This week on Biotech Nation, Heather Turner of LB Pharmaceuticals joins to discuss a drug that’s new to the US, but not-so-new to Europe, where it’s already been in use for a couple of years. Intended for managing neuropsychiatric conditions like Schizophrenia, the drug is taken by several million people, but the approval process in the US has had to start back at square one. We look at why that is, and how LB is working on it. 

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Moira Gunn. Innehållet i podden är skapat av Moira Gunn och inte av, eller tillsammans med, Poddtoppen.